225 related articles for article (PubMed ID: 36732815)
1. Proteomic analysis predicts anti-angiogenic resistance in recurred glioblastoma.
Jeon H; Byun J; Kang H; Kim K; Lee E; Kim JH; Hong CK; Song SW; Kim YH; Chong S; Kim JH; Nam SJ; Park JE; Lee S
J Transl Med; 2023 Feb; 21(1):69. PubMed ID: 36732815
[TBL] [Abstract][Full Text] [Related]
2. Anti-angiogenic therapy for high-grade glioma.
Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
[TBL] [Abstract][Full Text] [Related]
3. Identification of transcriptome signature for predicting clinical response to bevacizumab in recurrent glioblastoma.
Choi SW; Shin H; Sa JK; Cho HJ; Koo H; Kong DS; Seol HJ; Nam DH
Cancer Med; 2018 May; 7(5):1774-1783. PubMed ID: 29573206
[TBL] [Abstract][Full Text] [Related]
4. Dynamic expression of 11 miRNAs in 83 consecutive primary and corresponding recurrent glioblastoma: correlation to treatment, time to recurrence, overall survival and MGMT methylation status.
Matos B; Bostjancic E; Matjasic A; Popovic M; Glavac D
Radiol Oncol; 2018 Nov; 52(4):422-432. PubMed ID: 30511935
[TBL] [Abstract][Full Text] [Related]
5. Surgical outcome and molecular pattern characterization of recurrent glioblastoma multiforme: A single-center retrospective series.
Montemurro N; Fanelli GN; Scatena C; Ortenzi V; Pasqualetti F; Mazzanti CM; Morganti R; Paiar F; Naccarato AG; Perrini P
Clin Neurol Neurosurg; 2021 Aug; 207():106735. PubMed ID: 34119900
[TBL] [Abstract][Full Text] [Related]
6. Integrative multi-omics characterization reveals sex differences in glioblastoma.
Jang B; Yoon D; Lee JY; Kim J; Hong J; Koo H; Sa JK
Biol Sex Differ; 2024 Mar; 15(1):23. PubMed ID: 38491408
[TBL] [Abstract][Full Text] [Related]
7. Preoperative biomarkers of tumour vascularity are elevated in patients with glioblastoma multiforme.
Bennett IE; Guo H; Kountouri N; D'abaco GM; Hovens CM; Moffat BA; Desmond P; Drummond K; Kaye AH; Morokoff AP
J Clin Neurosci; 2015 Nov; 22(11):1802-8. PubMed ID: 26308396
[TBL] [Abstract][Full Text] [Related]
8. Single-cell RNA sequencing reveals tumor heterogeneity, microenvironment, and drug-resistance mechanisms of recurrent glioblastoma.
Wu H; Guo C; Wang C; Xu J; Zheng S; Duan J; Li Y; Bai H; Xu Q; Ning F; Wang F; Yang Q
Cancer Sci; 2023 Jun; 114(6):2609-2621. PubMed ID: 36853018
[TBL] [Abstract][Full Text] [Related]
9. Integrative analysis of transcriptome and proteome profiles in primary and recurrent glioblastoma.
Zhang J; Wang G; Yan B; Yang G; Yang Q; Hu Y; Guo J; Zhao N; Wang L; Wang H
Proteomics Clin Appl; 2024 May; 18(3):e2200085. PubMed ID: 38037768
[TBL] [Abstract][Full Text] [Related]
10. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
[TBL] [Abstract][Full Text] [Related]
11. Both p53 codon 72 Arg/Arg and pro/Arg genotypes in glioblastoma multiforme are associated with a better prognosis in bevacizumab treatment.
Shen CC; Cheng WY; Lee CH; Dai XJ; Chiao MT; Liang YJ; Hsieh WY; Mao TF; Lin GS; Chen SR; Liu BS; Chen JP
BMC Cancer; 2020 Jul; 20(1):709. PubMed ID: 32727419
[TBL] [Abstract][Full Text] [Related]
12. Integration of RNA-Seq and proteomics data identifies glioblastoma multiforme surfaceome signature.
Syafruddin SE; Nazarie WFWM; Moidu NA; Soon BH; Mohtar MA
BMC Cancer; 2021 Jul; 21(1):850. PubMed ID: 34301218
[TBL] [Abstract][Full Text] [Related]
13. Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme.
Verhoeff JJ; van Tellingen O; Claes A; Stalpers LJ; van Linde ME; Richel DJ; Leenders WP; van Furth WR
BMC Cancer; 2009 Dec; 9():444. PubMed ID: 20015387
[TBL] [Abstract][Full Text] [Related]
14. Survival kinase genes present prognostic significance in glioblastoma.
Varghese RT; Liang Y; Guan T; Franck CT; Kelly DF; Sheng Z
Oncotarget; 2016 Apr; 7(15):20140-51. PubMed ID: 26956052
[TBL] [Abstract][Full Text] [Related]
15. Targeted Proteomics to Assess the Response to Anti-Angiogenic Treatment in Human Glioblastoma (GBM).
Demeure K; Fack F; Duriez E; Tiemann K; Bernard A; Golebiewska A; Bougnaud S; Bjerkvig R; Domon B; Niclou SP
Mol Cell Proteomics; 2016 Feb; 15(2):481-92. PubMed ID: 26243272
[TBL] [Abstract][Full Text] [Related]
16. Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials.
Ellingson BM; Harris RJ; Woodworth DC; Leu K; Zaw O; Mason WP; Sahebjam S; Abrey LE; Aftab DT; Schwab GM; Hessel C; Lai A; Nghiemphu PL; Pope WB; Wen PY; Cloughesy TF
Neuro Oncol; 2017 Jan; 19(1):89-98. PubMed ID: 27580889
[TBL] [Abstract][Full Text] [Related]
17. Magnetic resonance perfusion image features uncover an angiogenic subgroup of glioblastoma patients with poor survival and better response to antiangiogenic treatment.
Liu TT; Achrol AS; Mitchell LA; Rodriguez SA; Feroze A; Iv M; Kim C; Chaudhary N; Gevaert O; Stuart JM; Harsh GR; Chang SD; Rubin DL
Neuro Oncol; 2017 Jul; 19(7):997-1007. PubMed ID: 28007759
[TBL] [Abstract][Full Text] [Related]
18. Neuropilin-1 modulates TGFβ signaling to drive glioblastoma growth and recurrence after anti-angiogenic therapy.
Kwiatkowski SC; Guerrero PA; Hirota S; Chen Z; Morales JE; Aghi M; McCarty JH
PLoS One; 2017; 12(9):e0185065. PubMed ID: 28938007
[TBL] [Abstract][Full Text] [Related]
19. A DNA Repair and Cell-Cycle Gene Expression Signature in Primary and Recurrent Glioblastoma: Prognostic Value and Clinical Implications.
Gobin M; Nazarov PV; Warta R; Timmer M; Reifenberger G; Felsberg J; Vallar L; Chalmers AJ; Herold-Mende CC; Goldbrunner R; Niclou SP; Van Dyck E
Cancer Res; 2019 Mar; 79(6):1226-1238. PubMed ID: 30674534
[TBL] [Abstract][Full Text] [Related]
20. EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma.
Hovinga KE; McCrea HJ; Brennan C; Huse J; Zheng J; Esquenazi Y; Panageas KS; Tabar V
J Neurooncol; 2019 Apr; 142(2):337-345. PubMed ID: 30680510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]